Q-TWiST Analysis Builds on LITESPARK-005 Efficacy of Belzutifan in ccRCC

Date: July 19, 2025

The Q-TWiST analysis from the LITESPARK-005 trial showed statistically significant improvement of belzutifan over everolimus in patients with clear cell RCC.

Perioperative Chemo Improves Survival, Control in Esophageal Cancer

Date: July 19, 2025

Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial.

Understanding Resistance to PSMA-Targeted Therapy

Date: July 19, 2025

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Date: July 19, 2025

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.

The OncFive: Top Oncology Articles for the Week of 7/13

Date: July 19, 2025

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

Darolutamide Shows Quality-of-Life Benefits in mHSPC, ARANOTE Trial Finds

Date: July 19, 2025

Alicia Morgans, MD, MPH, discusses how the ARANOTE trial not only demonstrated clinical efficacy for the combination of ADT and darolutamide, but also highlighted key quality-of-life benefits that could help inform patient and physician conversations.

Pooled Trial Data Highlight Potential of a Novel Biparatopic ADC in Heavily Pretreated HER2+ Breast Cancer

Date: July 19, 2025

JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.

Potential Biomarker May Predict Outcomes/Response in RCC

Date: July 18, 2025

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.

Casdatifan +/- Cabozantinib Showed Early Efficacy, Safety in Pretreated RCC

Date: July 18, 2025

Patients with RCC who received 100 mg once daily casdatifan had an ORR of 33%, and those who received casdatifan plus cabozantinib had an ORR of 46%.

Dr Hammers on the Efficacy of IO/TKI and IO/IO Regimens in ccRCC

Date: July 18, 2025

Hans Hammers, MD, PhD, discusses the main efficacy differences between IO/TKI and IO/IO combinations in clear-cell renal cell carcinoma.

Casdatifan Plus Cabozantinib Shows Meaningful Clinical Activity in Pretreated ccRCC

Date: July 18, 2025

Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.

High Levels of CD163+ Tumor-Associated Macrophages Could Improve Outcomes With Nivolumab in Metastatic RCC

Date: July 18, 2025

High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.

Q-TWiST Analysis Assesses Progression/Toxicity of Belzutifan Vs Everolimus in ccRCC

Date: July 18, 2025

Results from a Q-TWiST analysis of the LITESPARK-005 trial showed a trend favoring belzutifan over everolimus for patients with clear cell RCC.

Dr Rugo on the Safety Profile of Alpelisib in PI3K-Mutant HR+/HER2– Advanced Breast Cancer

Date: July 18, 2025

Hope S. Rugo, MD, discusses the safety profile of alpelisib for the treatment of PI3K-mutant HR-positive/HER2-negative advanced breast cancer.

Dr Maese on the Use of Pediatric-Inspired Regimens in AYA and Adult ALL

Date: July 18, 2025

Luke Maese, DO, discusses how the evolution of AYA and adult ALL management may be inspired by treatment protocols used in the pediatric population.

KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC

Date: July 18, 2025

KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.

Dr Kotecha on the Potential of ENPP3 as a Therapeutic Target in ccRCC

Date: July 18, 2025

Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.

Carotuximab Shows Promising Safety in Metastatic CRPC Phase 2 Trial

Date: July 18, 2025

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for patients with limited options.

Pembrolizumab/Lenvatinib Combination Produces Durable Responses in Advanced Non–Clear Cell RCC

Date: July 18, 2025

Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Pembrolizumab Combo Yields Enduring Activity in Advanced Non-Clear Cell RCC

Date: July 18, 2025

Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

Cancer-Fighting Herpes Virus Shown to be an Effective Treatment for Some Advanced Melanoma

Date: July 18, 2025

A genetically engineered herpes simplex virus plus immunotherapy reduces or eliminates tumors in 1/3 of clinical trial patients, according to a new study.

Adjuvant Immunotherapy in High-Risk CSCC: Dr Koyfman’s KEYNOTE-630 Insights

Date: July 18, 2025

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical trials.

FDA Issues CRL for Glofitamab Plus Chemo in R/R DLBCL

Date: July 18, 2025

The FDA issued a CRL to the application for glofitamab plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.

Dr Sabari on Efficacy of Zidesamtinib in TKI-Pretreated, Advanced, ROS1+ NSCLC

Date: July 18, 2025

Joshua K. Sabari, MD, discusses response rates observed with zidesamtinib in patients with advanced ROS1-positive non–small cell lung cancer.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Date: July 18, 2025

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Mulligan on the Quest for Optimal Combinations in Myeloma Treatment

Date: July 18, 2025

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

Luspatercept Plus Concomitant JAK Inhibitor Therapy Misses Primary End Point in Myelofibrosis-Associated Anemia

Date: July 18, 2025

Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.

Optimizing AML Treatment: ICT01 Receives FDA Orphan Drug Designation

Date: July 18, 2025

FDA Grants Orphan Drug Designation to ICT01 for Acute Myeloid Leukemia

Date: July 18, 2025

ICT01 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.

Dr Runcie on Treatment Approaches in RCC After Progression on Adjuvant Therapy

Date: July 18, 2025

Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.

New Hope for Anal Cancer: Retifanlimab Extends Progression-Free Survival

Date: July 18, 2025